Yellox 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
IA/0032 
B.II.d.1.c - Change in the specification parameters 
06/09/2022 
n/a 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
T/0031 
Transfer of Marketing Authorisation 
10/01/2022 
04/02/2022 
SmPC, 
Labelling and 
PL 
PSUSA/436/2
Periodic Safety Update EU Single assessment - 
13/01/2022 
n/a 
PRAC Recommendation - maintenance 
02105 
bromfenac 
IA/0030 
B.II.d.1.a - Change in the specification parameters 
02/12/2021 
n/a 
and/or limits of the finished product - Tightening of 
specification limits 
IB/0028/G 
This was an application for a group of variations. 
01/09/2021 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.a.2.e - Changes in the manufacturing process of 
the AS - Minor change to the restricted part of an 
ASMF 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
Page 2/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0027/G 
This was an application for a group of variations. 
11/05/2021 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.I.a.1.f - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - 
Changes to quality control testing arrangements for 
the AS -replacement or addition of a site where 
batch control/testing takes place 
IB/0026 
C.I.z - Changes (Safety/Efficacy) of Human and 
27/10/2020 
15/11/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
T/0024 
Transfer of Marketing Authorisation 
23/04/2020 
14/05/2020 
SmPC, 
Labelling and 
PL 
PSUSA/436/2
Periodic Safety Update EU Single assessment - 
16/01/2020 
n/a 
PRAC Recommendation - maintenance 
01905 
bromfenac 
IA/0022 
B.II.b.2.a - Change to importer, batch release 
04/06/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/436/2
Periodic Safety Update EU Single assessment - 
11/01/2018 
n/a 
PRAC Recommendation - maintenance 
01705 
bromfenac 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0020 
B.II.b.2.a - Change to importer, batch release 
04/05/2017 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
N/0019 
Minor change in labelling or package leaflet not 
05/04/2017 
26/07/2017 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
PSUSA/436/2
Periodic Safety Update EU Single assessment - 
12/01/2017 
n/a 
PRAC Recommendation - maintenance 
01605 
bromfenac 
IA/0017 
A.7 - Administrative change - Deletion of 
24/08/2016 
26/07/2017 
Annex II and 
manufacturing sites 
PL 
IA/0016 
A.7 - Administrative change - Deletion of 
21/07/2016 
n/a 
manufacturing sites 
IA/0015 
B.I.a.4.a - Change to in-process tests or limits 
05/07/2016 
n/a 
applied during the manufacture of the AS - 
Tightening of in-process limits 
PSUSA/436/2
Periodic Safety Update EU Single assessment - 
14/01/2016 
n/a 
PRAC Recommendation - maintenance 
01505 
bromfenac 
R/0014 
Renewal of the marketing authorisation. 
19/11/2015 
11/01/2016 
SmPC, Annex 
The renewal has been granted with unlimited validity. 
II/0013/G 
This was an application for a group of variations. 
24/09/2015 
n/a 
B.II.e.1.b.2 - Change in immediate packaging of the 
II, Labelling 
and PL 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
finished product - Change in type/addition of a new 
container - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.e.7.b - Change in supplier of packaging 
components or devices (when mentioned in the 
dossier) - Replacement or addition of a supplier 
PSUV/0010 
Periodic Safety Update 
18/12/2014 
26/02/2015 
SmPC and PL 
Please refer to Yellow PSUV-0010 EPAR: 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
T/0011 
Transfer of Marketing Authorisation 
06/11/2014 
27/01/2015 
SmPC, 
Labelling and 
PL 
IB/0009 
B.II.b.4.a - Change in the batch size (including batch 
07/08/2014 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
PSUV/0007 
Periodic Safety Update 
13/06/2014 
n/a 
PRAC Recommendation - maintenance 
IAIN/0008 
C.I.8.a - Introduction of or changes to a summary of 
08/05/2014 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0006 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/08/2013 
27/01/2015 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0005 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/05/2013 
n/a 
Veterinary Medicinal Products - Other variation 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0004 
C.I.9.c - Changes to an existing pharmacovigilance 
15/10/2012 
n/a 
system as described in the DDPS - Change of the 
back-up procedure of the QPPV 
IAIN/0003 
C.I.9.a - Changes to an existing pharmacovigilance 
21/09/2012 
n/a 
system as described in the DDPS - Change in the 
QPPV 
IB/0002 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
07/12/2011 
06/02/2012 
SmPC and 
life of the finished product - As packaged for sale 
Labelling 
(supported by real time data) 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
18/07/2011 
n/a 
SmPC and PL 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
